- Home
- SGLY vs AYTU Comparison
SGLY vs AYTU Comparison
Compare SGLY & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- AYTU
- Stock Information
- Founded
- SGLY 2001
- AYTU N/A
- Country
- SGLY United States
- AYTU United States
- Employees
- SGLY N/A
- AYTU N/A
- Industry
- SGLY
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- AYTU Health Care
- Exchange
- SGLY Nasdaq
- AYTU Nasdaq
- Market Cap
- SGLY 3.4M
- AYTU 23.0M
- IPO Year
- SGLY 2008
- AYTU N/A
- Fundamental
- Price
- SGLY $0.61
- AYTU $2.04
- Analyst Decision
- SGLY
- AYTU Strong Buy
- Analyst Count
- SGLY 0
- AYTU 3
- Target Price
- SGLY N/A
- AYTU $9.17
- AVG Volume (30 Days)
- SGLY 114.8K
- AYTU 85.3K
- Earning Date
- SGLY 11-14-2025
- AYTU 11-13-2025
- Dividend Yield
- SGLY N/A
- AYTU N/A
- EPS Growth
- SGLY N/A
- AYTU N/A
- EPS
- SGLY N/A
- AYTU N/A
- Revenue
- SGLY $1,813,193.00
- AYTU $66,382,000.00
- Revenue This Year
- SGLY N/A
- AYTU N/A
- Revenue Next Year
- SGLY N/A
- AYTU $29.12
- P/E Ratio
- SGLY N/A
- AYTU N/A
- Revenue Growth
- SGLY N/A
- AYTU 1.84
- 52 Week Low
- SGLY $0.54
- AYTU $0.95
- 52 Week High
- SGLY $5.49
- AYTU $2.82
- Technical
- Relative Strength Index (RSI)
- SGLY 33.53
- AYTU 39.21
- Support Level
- SGLY $0.57
- AYTU $1.80
- Resistance Level
- SGLY $0.64
- AYTU $2.21
- Average True Range (ATR)
- SGLY 0.05
- AYTU 0.14
- MACD
- SGLY 0.00
- AYTU -0.02
- Stochastic Oscillator
- SGLY 9.32
- AYTU 39.64
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.